Cargando…
Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome
Loss-of-function mutations in SCN1A cause Dravet syndrome (DS), a catastrophic childhood epilepsy in which patients experience comorbid behavioral conditions, including movement disorders, sleep abnormalities, anxiety, and intellectual disability. To study the functional consequences of voltage-gate...
Autores principales: | Grone, Brian P., Qu, Tiange, Baraban, Scott C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555352/ https://www.ncbi.nlm.nih.gov/pubmed/28812061 http://dx.doi.org/10.1523/ENEURO.0066-17.2017 |
Ejemplares similares
-
Drug repurposing for Dravet syndrome in scn1Lab
(−/−) mutant zebrafish
por: Sourbron, Jo, et al.
Publicado: (2019) -
Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet Syndrome treatment
por: Baraban, Scott C., et al.
Publicado: (2013) -
Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome1,2,3
por: Dinday, Matthew T., et al.
Publicado: (2015) -
Altered Glycolysis and Mitochondrial Respiration in a Zebrafish Model of Dravet Syndrome123
por: Kumar, Maneesh G., et al.
Publicado: (2016) -
Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
por: Griffin, Aliesha, et al.
Publicado: (2018)